Skip to content
Menu

HC Wainwright & Co. Maintains Buy on Crescent Biopharma, Raises Price Target to $40

Benzinga Newsdesk 1 week ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Crescent Biopharma (NASDAQ:CBIO) with a Buy and raises the price target from $36 to $40.

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Crescent Biopharma (NASDAQ:CBIO) with a Buy and raises the price target from $36 to $40.

Read at benzinga.com

← All stock news